Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gene Therapeutics & RNAiGene Therapy

PUBLISHER: Grand View Research | PRODUCT CODE: 1404639

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1404639

Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type (Lentivirus, Adenovirus), By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 162 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Gene Therapy Market Growth & Trends:

The global gene therapy market is expected to reach USD 29.51 billion by 2030, registering a CAGR of 19.5% from 2023 to 2030, according to a new report by Grand View Research, Inc. The development of the market is owing to an increase in the number of gene therapy-based discoveries, increasing investment in this sector, and rising approval of gene therapy products. According to the WHO, 10 to 20 new cell and gene therapies are expected to be approved each year by 2025.

Continuous developments in recombinant DNA technology are anticipated to enhance the efficiency of gene therapy in the coming years. Hence, ongoing progresses in recombinant DNA technology are anticipated to expand the number of ongoing clinical trials for gene therapy. Primarily, these advancements are taking place in the context of various gene-editing tools and expression systems to augment the R&D for products. The advent of CRISPR/Cas9 nuclease, ZFN, and TALEN allows easy & precise genome editing. As a result, in recent times, the gene-editing space has witnessed a substantial number of research activities, which, in turn, is expected to influence the growth of the gene therapy market.

The growth of the gene therapy market is expected to be majorly benefitted from the increasing prevalence of cancer. The ongoing increase in cancer patients and related death per year emphasizes the essential for the development of robust treatment solutions. In 2020, there were around 18.1 million new cases of cancer worldwide. 9.3 million of these cases involved men, while 8.8 million involved women. Continuing developments in tumor genetic studies have delivered substantial information about cancer-related molecular signatures, which in turn, is expected to support ongoing clinical trials for cancer therapeutics.

With rising demand for robust disease treatment therapies, companies have focused their efforts to accelerate R&D for effective genetic therapies that target the cause of disease at a genomic level. . Furthermore, the U.S. FDA provides constant support for innovations in this sector via a number of policies with regard to product manufacturing. In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe and efficient products.

Furthermore, facility expansion for cell and gene therapies is one of the major factors driving the gene therapy market growth. Several in-house facilities and CDMOs for gene therapy manufacturing have begun investing to enhance their production capacity, which, in turn, is anticipated to create lucrative opportunities for market players. For instance, in April 2022, the FDA approved commercial licensure approval to Novartis for its Durham, N.C. site. This approval permits the 170,000 square-foot facility to make, test, and issue commercial Zolgensma, as well as manufacture therapy products for current & upcoming clinical trials.

Gene Therapy Market Report Highlights:

  • The AAV segment shows a significant revenue contribution of 22% in 2023. Several biopharma companies are offering their viral vector platform for the development of AAV-based gene therapy product.
  • By indication, the spinal muscular atrophy (SMA) segment dominated the market in 2023 with a share of 46.8%. Although SMA is a rare disorder, it is one of the most common fatal inherited diseases of infancy.
  • The Beta-Thalassemia Major/SCD segment is anticipated to register the fastest CAGR of 38.3% over the forecast period. Gene therapy for SCD and B-thalassemia is based on transplantation of gene-modified hematopoietic stem cells.
  • North America dominated the market in 2023 with the largest revenue share of 65.2% in 2023. This region is expected to become the largest routine manufacturer of gene therapy in terms of the number of approvals and revenue generated during the forecast period.
  • Europe is estimated to be the fastest-growing regional segment from 2024 to 2030. This is attributed to its large population with unmet medical needs and increasing demand for novel technologies in the treatment of rare but increasingly prevalent diseases.
Show more
Product Code: GVR-2-68038-179-5

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Information Analysis
    • 1.2.2. Market Application & Data Visualization
    • 1.2.3. Data Validation & Publishing
  • 1.3. Research Assumptions
  • 1.4. Information Procurement
    • 1.4.1. Primary Research
  • 1.5. Information or Data Analysis
  • 1.6. Market Application & Validation
  • 1.7. Market Model
  • 1.8. Global Market: CAGR Calculation
  • 1.9. Objectives
    • 1.9.1. Objective 1:
    • 1.9.2. Objective 2:

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Robust Gene Therapy Pipeline
      • 3.2.1.2. Introduction Of Technological Advancements
      • 3.2.1.3. Increasing Investment From Companies And Partnerships
      • 3.2.1.4. Growing Prevalence Of Target Diseases And Increased Demand For Innovative Medicine
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Absence Of Effective Diagnosis Framework
      • 3.2.2.2. High Prices Of Gene Therapy
    • 3.2.3. Market Opportunity Analysis
      • 3.2.3.1. Rising Investment For Adoptive T-Cell Transfer Approaches Of Disease Treatment
      • 3.2.3.2. Facility Expansion For Cell And Gene Therapies
      • 3.2.3.3. Technological Advancements In Manufacturing Vectors
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Indication Business Analysis

  • 4.1. Gene Therapy Market: Indication Movement Analysis
  • 4.2. Acute Lymphoblastic Leukemia
    • 4.2.1. Acute Lymphoblastic Leukemia Market, 2018 - 2030 (USD Million)
  • 4.3. Inherited Retinal Disease
    • 4.3.1. Inherited Retinal Disease Market, 2018 - 2030 (USD Million)
  • 4.4. Large B-Cell Lymphoma
    • 4.4.1. Large B-Cell Lymphoma Market, 2018 - 2030 (USD Million)
  • 4.5. Adenosine Deaminase (Ada)-Deficient Severe Combined Immunodeficiency (Scid)
    • 4.5.1. Adenosine Deaminase (Ada)-Deficient Severe Combined Immunodeficiency (Scid) Market, 2018 - 2030 (USD Million)
  • 4.6. Melanoma (lesions)
    • 4.6.1. Melanoma (lesions) Market, 2018 - 2030 (USD Million)
  • 4.7. Beta-Thalassemia Major/Sickle Cell Disease (Scd)
    • 4.7.1. Beta-Thalassemia Major/Sickle Cell Disease (Scd) Market, 2018 - 2030 (USD Million)
  • 4.8. Head & Neck Squamous Cell Carcinoma
    • 4.8.1. Head & Neck Squamous Cell Carcinoma Market, 2018 - 2030 (USD Million)
  • 4.9. Peripheral arterial disease
    • 4.9.1. Peripheral arterial disease Market, 2018 - 2030 (USD Million)
  • 4.10. Spinal Muscular Atrophy (SMA)
    • 4.10.1. Spinal Muscular Atrophy (SMA) Market, 2018 - 2030 (USD Million)
  • 4.11. Others
    • 4.11.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Vector Type Business Analysis

  • 5.1. Gene Therapy Market: Vector Type Movement Analysis
  • 5.2. Lentiviral Vectors
    • 5.2.1. Lentiviral Vectors market, 2018 - 2030 (USD Million)
  • 5.3. Adeno-Associated Viral (Aav) Vectors
    • 5.3.1. Adeno-Associated Viral (Aav) Vectors market, 2018 - 2030 (USD Million)
  • 5.4. Retrovirus Vectors
    • 5.4.1. Retrovirus Vectors market, 2018 - 2030 (USD Million)
  • 5.5. Modified Herpes Simplex Virus
    • 5.5.1. Modified Herpes Simplex Virus market, 2018 - 2030 (USD Million)
  • 5.6. Adenovirus Vectors
    • 5.6.1. Adenovirus Vectors market, 2018 - 2030 (USD Million)
  • 5.7. Non-Viral Plasmid Vector
    • 5.7.1. Non-Viral Plasmid Vector market, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Gene Therapy Market Share By Region, 2023 & 2030
  • 6.2. North America
    • 6.2.1. North America Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. Key Country Dynamics
      • 6.2.2.2. Target disease prevalence
      • 6.2.2.3. Competitive Scenario
      • 6.2.2.4. Regulatory Framework
      • 6.2.2.5. U.S. Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Target disease prevalence
      • 6.2.3.3. Competitive Scenario
      • 6.2.3.4. Regulatory Framework
      • 6.2.3.5. Canada Gene Therapy Market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Target disease prevalence
      • 6.3.2.3. Competitive Scenario
      • 6.3.2.4. Regulatory Framework
      • 6.3.2.5. UK Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target disease prevalence
      • 6.3.3.3. Competitive Scenario
      • 6.3.3.4. Regulatory Framework
      • 6.3.3.5. Germany Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Target disease prevalence
      • 6.3.4.3. Competitive Scenario
      • 6.3.4.4. Regulatory Framework
      • 6.3.4.5. France Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Target disease prevalence
      • 6.3.5.3. Competitive Scenario
      • 6.3.5.4. Regulatory Framework
      • 6.3.5.5. Italy Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Target disease prevalence
      • 6.3.6.3. Competitive Scenario
      • 6.3.6.4. Regulatory Framework
      • 6.3.6.5. Spain Gene Therapy Market, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target disease prevalence
      • 6.4.2.3. Competitive Scenario
      • 6.4.2.4. Regulatory Framework
      • 6.4.2.5. Japan Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target disease prevalence
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Regulatory Framework
      • 6.4.3.5. China Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.4.4. Australia
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target disease prevalence
      • 6.4.4.3. Competitive Scenario
      • 6.4.4.4. Regulatory Framework
      • 6.4.4.5. Australia Gene Therapy Market, 2018 - 2030 (USD Million)
  • 6.5. Rest of the world
    • 6.5.1. Rest of the world Gene Therapy Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Share Analysis, 2023
  • 7.4. Company Profiles
    • 7.4.1. REGENXBIO, INC
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. OXFORD BIOMEDICA PLC
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. VOYAGER THERAPEUTICS
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. HUMAN STEM CELLS INSTITUTE
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. DIMENSION THERAPEUTICS, INC
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. BRISTOL-MYERS SQUIBB COMPANY
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. SANOFI
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. APPLIED GENETIC TECHNOLOGIES CORPORATION
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. F. HOFFMANN-LA ROCHE LTD
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. BLUEBIRD BIO, INC
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. NOVARTIS AG
      • 7.4.11.1. Overview
      • 7.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Strategic Initiatives
    • 7.4.12. TAXUS CARDIUM PHARMACEUTICALS GROUP, INC. (GENE BIOTHERAPEUTICS)
      • 7.4.12.1. Overview
      • 7.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.12.3. Product Benchmarking
      • 7.4.12.4. Strategic Initiatives
    • 7.4.13. UNIQURE N.V.
      • 7.4.13.1. Overview
      • 7.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.13.3. Product Benchmarking
      • 7.4.13.4. Strategic Initiatives
    • 7.4.14. TAKEDA PHARMACEUTICAL COMPANY LIMITED
      • 7.4.14.1. Overview
      • 7.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.14.3. Product Benchmarking
      • 7.4.14.4. Strategic Initiatives
    • 7.4.15. CELLECTIS S.A.
      • 7.4.15.1. Overview
      • 7.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.15.3. Product Benchmarking
      • 7.4.15.4. Strategic Initiatives
    • 7.4.16. SANGAMO THERAPEUTICS, INC.
      • 7.4.16.1. Overview
      • 7.4.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.16.3. Product Benchmarking
      • 7.4.16.4. Strategic Initiatives
    • 7.4.17. ORCHARD THERAPEUTICS
      • 7.4.17.1. Overview
      • 7.4.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.17.3. Product Benchmarking
      • 7.4.17.4. Strategic Initiatives
    • 7.4.18. GILEAD LIFESCIENCES, INC.
      • 7.4.18.1. Overview
      • 7.4.18.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.18.3. Product Benchmarking
      • 7.4.18.4. Strategic Initiatives
    • 7.4.19. BENITEC BIOPHARMA
      • 7.4.19.1. Overview
      • 7.4.19.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.19.3. Product Benchmarking
      • 7.4.19.4. Strategic Initiatives
    • 7.4.20. SIBIONO GENETECH CO., LTD
      • 7.4.20.1. Overview
      • 7.4.20.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.20.3. Product Benchmarking
      • 7.4.20.4. Strategic Initiatives
    • 7.4.21. SHANGHAI SUNWAY BIOTECH CO., LTD.
      • 7.4.21.1. Overview
      • 7.4.21.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.21.3. Product Benchmarking
      • 7.4.21.4. Strategic Initiatives
    • 7.4.22. GENSIGHT BIOLOGICS S.A.
      • 7.4.22.1. Overview
      • 7.4.22.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.22.3. Product Benchmarking
      • 7.4.22.4. Strategic Initiatives
    • 7.4.23. TRANSGENE
      • 7.4.23.1. Overview
      • 7.4.23.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.23.3. Product Benchmarking
      • 7.4.23.4. Strategic Initiatives
    • 7.4.24. CALIMMUNE, INC
      • 7.4.24.1. Overview
      • 7.4.24.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.24.3. Product Benchmarking
      • 7.4.24.4. Strategic Initiatives
    • 7.4.25. EPEIUS BIOTECHNOLOGIES CORP.
      • 7.4.25.1. Overview
      • 7.4.25.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.25.3. Product Benchmarking
      • 7.4.25.4. Strategic Initiatives
    • 7.4.26. ASTELLAS PHARMA INC
      • 7.4.26.1. Overview
      • 7.4.26.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.26.3. Product Benchmarking
      • 7.4.26.4. Strategic Initiatives
    • 7.4.27. AMERICAN GENE TECHNOLOGIES
      • 7.4.27.1. Overview
      • 7.4.27.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.27.3. Product Benchmarking
      • 7.4.27.4. Strategic Initiatives
    • 7.4.28. BIOMARIN PHARMACEUTICALS, INC
      • 7.4.28.1. Overview
      • 7.4.28.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.28.3. Product Benchmarking
      • 7.4.28.4. Strategic Initiatives
Show more
Product Code: GVR-2-68038-179-5

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Tables
  • Table 3 List of Secondary Sources
  • Table 4 List of Abbreviations
  • Table 5 Global Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 6 Global Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 7 Global Gene Therapy Market by Region, 2018 - 2030 (USD Million)
  • Table 8 North America Gene Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 10 North America Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 11 U.S. Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 13 Canada Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 15 Europe Gene Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 16 Europe Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 17 Europe Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 18 Germany Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 19 Germany Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 20 UK Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 21 UK Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 22 France Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 23 France Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 24 Italy Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 25 Italy Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 26 Spain Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 27 Spain Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific Gene Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 31 China Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 32 China Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 33 Japan Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 34 Japan Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 35 South Korea Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 36 South Korea Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 37 Australia Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 38 Australia Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 39 RoW Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 40 RoW Gene Therapy Market by Indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Gene Therapy Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 10 Penetration & Growth Prospect Mapping
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 Regional Marketplace: Key Takeaways
  • Fig. 14 Global Gene Therapy Market for Lentivirus, 2018 - 2030 (USD Million)
  • Fig. 15 Global Gene Therapy Market for AAV, 2018 - 2030 (USD Million)
  • Fig. 16 Global Gene Therapy Market for RetroVirus & gamma RetroVirus, 2018 - 2030 (USD Million)
  • Fig. 17 Global Gene Therapy Market for Modified Herpes Simplex Virus, 2018 - 2030 (USD Million)
  • Fig. 18 Global Gene Therapy Market for Adenovirus, 2018 - 2030 (USD Million)
  • Fig. 19 Global Gene Therapy Market for Non-viral Plasmid Vector, 2018 - 2030 (USD Million)
  • Fig. 20 Global Gene Therapy Market for Other Vector Type, 2018 - 2030 (USD Million)
  • Fig. 21 Global Gene Therapy Market for Acute Lymphoblastic Leukemia (ALL), 2018 - 2030 (USD Million)
  • Fig. 22 Global Acute Lymphoblastic Leukemia (ALL) patients treated with gene therapy, 2018 - 2030
  • Fig. 23 Global Gene Therapy Market for Inherited Retinal Disease, 2018 - 2030 (USD Million)
  • Fig. 24 Global Inherited Retinal Disease patients treated with gene therapy, 2018 - 2030
  • Fig. 25 Global Gene Therapy Market for Large B-cell Lymphoma, 2018 - 2030 (USD Million)
  • Fig. 26 Global Large B-cell Lymphoma patients treated with gene therapy, 2018 - 2030
  • Fig. 27 Global Gene Therapy Market for ADA-SCID, 2018 - 2030 (USD Million)
  • Fig. 28 Global ADA-SCID patients treated with gene therapy, 2018 - 2030
  • Fig. 29 Global Gene Therapy Market for Melanoma (lesions), 2018 - 2030 (USD Million)
  • Fig. 30 Global Melanoma (lesions) patients treated with gene therapy, 2018 - 2030
  • Fig. 31 Global Gene Therapy Market for Beta-Thalassemia Major/SCD, 2018 - 2030 (USD Million)
  • Fig. 32 Global Beta-Thalassemia Major/SCD patients treated with gene therapy, 2018 - 2030
  • Fig. 33 Global Gene Therapy Market for Head & Neck Squamous Cell Carcinoma, 2018 - 2030 (USD Million)
  • Fig. 34 Global Head & Neck Squamous Cell Carcinoma patients treated with gene therapy, 2018 - 2030
  • Fig. 35 Global Gene Therapy Market for Peripheral arterial disease, 2018 - 2030 (USD Million)
  • Fig. 36 Global Peripheral arterial disease patients treated with gene therapy, 2018 - 2030
  • Fig. 37 Global Gene Therapy Market for Spinal Muscular Atrophy (SMA), 2018 - 2030 (USD Million)
  • Fig. 38 Global Spinal Muscular Atrophy (SMA) patients treated with gene therapy, 2018 - 2030
  • Fig. 39 Global Gene Therapy Market for Others, 2018 - 2030 (USD Million)
  • Fig. 40 Global Other diseases patient treated with gene therapy, 2018 - 2030
  • Fig. 41 Regional Outlook, 2022 & 2030
  • Fig. 42 North America Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 44 Canada Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 45 Europe Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 46 Germany Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 47 UK Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 48 France Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 49 Italy Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 50 Spain Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 52 Japan Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 53 China Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 54 Australia Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 55 South Korea Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 56 Rest of the world Gene Therapy Market 2018 - 2030 (USD Million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!